Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
Date:11/2/2007

LOS ANGELES, Nov. 2 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "We believe Raptor's operational approach will serve as the template for all small cap biotechnology companies as it promotes operational efficiency, reduced operating costs and efficient allocation of human resources. Also, Raptor now has a Phase II candidate for 2008 in Convivia(TM), which will treat a large patient population in a billion dollar plus market," stated Ross Silver, Director of Research for Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com.

Raptor's CEO, Dr. Christopher M. Starr, is presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at The New York Palace Hotel on Monday, November 5, 2007 at 4:05 p.m. ET. A webcast of Dr. Starr's presentation, including slides, will be posted on Raptor's website, live and archived for 90 days.

About Raptor:

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of Raptor Pharmaceutical Inc. ("Raptor Inc."), a development stage biotechnology company which bioengineers novel drug candidates and drug- targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company formed to develop clinical-stage products to marketing approval and commercialization. Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand its coverage in specific disease indications.

Bennu's initial clinical program includes the treatment of aldehyde dehydrogenase ("ALDH2") deficiency. For additional information, please visit http://www.raptorpharma.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... Dr. Travis Schwarz is an experienced dentist who leads ... 63366. He serves patients of all ages with a full menu of dental services, ... reflected in the superior patient reviews that he has consistently earned during his practice ...
(Date:5/25/2016)... NY (PRWEB) , ... May 25, 2016 , ... Today ... the launch of 11 innovative workshops and training opportunities in the growing ... the unique needs of individuals who are dealing with specific health issues—including injuries, illnesses, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... The ... dive into the unique integrative medical wellness offerings of Europe, a continent that pioneered ... Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, Founder ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology: